Loading...

Antisense Therapeutics Limited

ANP.AX•ASX
HealthcareDrug Manufacturers - Specialty & Generic
A$0.06
A$-0.00(-4.92%)

Antisense Therapeutics Limited (ANP.AX) Stock Overview

Explore Antisense Therapeutics Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ANP.AXStats details for ANP.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ANP.AXAnalyst Recommendations details for ANP.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

CEO

Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA

Employees

8

Headquarters

14 Wallace Avenue, Toorak, VIC

Founded

2001

Frequently Asked Questions